Edgewise Therapeutics started at outperform with $38 stock price target at Wedbush

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Edgewise Therapeutics Inc.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply